Genmab — Juni 2023
-
@lahn1 JNJ opting in to Hexabody-CD38 would be by far the easiest and i imagine would get a very positive market reaction. It proofs JNJ believes in the product and they will take over all development and costs. But lately i have been wondering more and more if it could not be more profitable for Genmab to develop it themselves for the areas you mention...
-
@g
-
@gdn55 - et supplerende spørgsmål til dit indlæg 14:32: Hvor i mine indlæg ser du, at jeg forventer Genmab fortsat vil falde? Mig bekendt, har jeg kun kommenteret på den udvikling, der er sket

-
@Sukkeralf. Hvor har du ret - men det er jo trådt lid i baggrunden efter 2 tabte voldgifter

-
Så er vi stort set ligestillede… jeg er årgang 53

-
Så er du jo forholdsvis ung

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind